Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism.
about
Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistanceResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsIn-depth phylogenetic analysis of hepatitis C virus subtype 1a and occurrence of 80K and associated polymorphisms in the NS3 proteaseClinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CTwo Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors.Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in SpainImplications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy.Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development.Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.Prevention and management of treatment failure to new oral hepatitis C drugs.New real-time-PCR method to identify single point mutations in hepatitis C virus.Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis.Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing SimeprevirResistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus.Resistance to DAAs: When to Look and When It Matters.Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus
P2860
Q26740219-E48BBA77-10CC-419B-B794-61AC3F43909CQ26777408-18E84423-4B06-4A94-9223-D4033D0718FBQ27468875-8D9D50A4-588B-49F0-9D41-894F2DB5342CQ28080225-38A2DB0F-96E4-4E92-9118-BB00114B594EQ35880497-AB753E0D-084B-4A6B-B941-E9FEB07219A2Q35917596-900B9E24-133E-4360-908F-767E5BD4E32CQ36148440-DA1CBCDB-7335-499B-B6E7-5765F0B85BEAQ36299928-A3E9056B-8662-47BE-86A5-6BB768D03A6FQ37354049-214A591F-DBA1-45B0-B762-322CEDDB6E30Q38367590-26F0C64C-AD9D-4409-B436-D505908C449EQ38826624-2DB07334-4BFC-453F-8ADA-94DC1327859EQ40422658-413E976B-3CF6-4C14-8A2A-19E4D758A32CQ40451354-96025E7B-80CE-47D9-A181-73C92A80D88CQ41127462-473286EB-0E46-4617-89A2-9E9742BD11AAQ41145466-2AE5BC26-41D5-4A26-9A0C-D44E2A835DB1Q47549498-36C62886-5651-4C14-958D-56CE39626897Q50108357-B8273B8A-9501-49DC-8444-035BABD4C341Q59126211-3876B8F2-4B63-4067-B4FB-4EE73A6E5C91
P2860
Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Global origin and transmission ...... l protein 3 Q80K polymorphism.
@en
type
label
Global origin and transmission ...... l protein 3 Q80K polymorphism.
@en
prefLabel
Global origin and transmission ...... l protein 3 Q80K polymorphism.
@en
P2093
P2860
P356
P1476
Global origin and transmission ...... l protein 3 Q80K polymorphism.
@en
P2093
Art F Y Poon
Jeffrey B Joy
P Richard Harrigan
Richard H Liang
Rosemary M McCloskey
P2860
P304
P356
10.1093/INFDIS/JIU613
P407
P577
2014-11-10T00:00:00Z